Thanks to this tiny piece of tech, people with profound vision loss can now read, do cross word puzzles, and navigate public ...

PCWorld's Adam Patrick Murray sat with the Senior VP of Software Development at AMD to talk about the future of Adrenalin ...

The 2026 CES parade of giant TVs and AI robots didn’t disappoint — but it’s the practical, useful gadgets that truly stole ...

KitGuru has been a fan of amd Ryzen processors for many years and the recent launch of the Ryzen 7 9800X3D confirms this ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...

Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using ...

CES 2026 was AMD's moment to shine in the light of the ongoing AI boom, offering more chips to drive AI compute and bringing ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...

The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials ...

Outlook Therapeutics said on Wednesday the U.S. health regulator has declined to approve its drug for a type of eye disease, ...